Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
About this trial
This is an interventional treatment trial for Recurrent Lung Non-Small Cell Carcinoma
Eligibility Criteria
Inclusion Criteria:
- Histological confirmation of non-small cell lung cancer
- Forced Expiratory volume in 1 second (FEV1)>1.0 L
Unresectable stage 2-3 Non-small cell lung cancer (based on CT/positron emission tomography (PET), MRI or CT of brain, and Physical exam).
• Eligible if recurrence after surgery and now has the equivalent stage 2-3 NSCLC OR had sub totally resected stage 2-3 NSCLC.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
- Negative pregnancy test done ≤7 days prior to registration, for women of childbearing potential only.
The following laboratory values in specified ranges:
- White blood cell count (WBC) ≥3.0 x 109/L,
- Absolute neutrophil count (ANC) ≥1.5 x 109/L,
- Hgb ≥9g/dl
- Plts >100 x 109/L
- Serum creatinine<1.5 times upper limit of normal (ULN)
- Serum bilirubin <1.5 times upper limit of normal (ULN)
- Provide informed written consent.
- Willing to return to enrolling institution for follow-up for a minimum of 1 year.
- Ability to undergo potentially curative chemotherapy plus radiotherapy
Exclusion Criteria:
Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
- Weight loss of >10% in the past 6 months
- Distant metastases (M1 disease)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, lupus, Usual interstitial pneumonitis (UIP), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Receiving any investigational agent, that would be considered as a treatment for the primary neoplasm.
- Other active malignancy ≤3 years prior to registration. EXCEPTIONS: treated non-melanotic skin cancer, carcinoma-in-situ of the cervix, treated Stage 1-2, Gleason 7 or less, prostate cancer with a stable or undetectable prostate specific antigen (PSA) level, treated stage 1 breast cancer which is controlled and for which the patient received no thoracic radiotherapy (RT).
- History of myocardial infarction ≤6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
- Received chemotherapy for lung cancer within 6 months of registration.
- Previous chest radiotherapy.
Sites / Locations
- Mayo Clinic in Arizona
- Mayo Clinic in Rochester
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Arm A (platinum doublet chemotherapy, lower dose PBT)
Arm C (platinum doublet chemotherapy, higher dose PBT)
Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity.
Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity.